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The draft human genome sequence and the dissemination of high throughput technology provides opportunities for system-
atic analysis of cancer cells. Genome-wide mutation screens, high resolution analysis of chromosomal abberations and
expression profiling all give comprehensive views of genetic alterations in cancer cells. From these analyses will come a
complete list of the genetic changes that drive malignant transformation and of the therapeutic targets that may be exploited
for clinical benefit.
Cancer is a disease of the genome, which is invariably altered
at multiple sites in cancer cells. The goal of cancer research is
to define these molecular defects and turn these discoveries
into effective treatment and prevention regimens. Until recently,
these efforts relied on laborious, and necessarily limited, one-
gene-at-a-time approaches. However, technological advances,
coupled with the draft human genome sequence, promise to
both accelerate this research and fundamentally change how
we think about cancer. Discrete molecular changes and the per-
turbation of associated pathways ultimately will be placed in
context, enabling construction of a multidimensional map of the
complex circuitry of cells and how it is altered in specific can-
cers. Subgroups of tumors will be defined by recurrent patterns
of alterations. Tumor classification, now based on morphology,
which is inexact, subject to marked interobserver variation, and
not grounded in biologic relevance, will be replaced by a molec-
ular classification scheme. Although to date, global expression
profiling has been central to developing novel molecular classifi-
cation schemes, a comprehensive mutation analysis, a whole
genome catalog of submicroscopic chromosomal aberrations,
or a global methylation scan will likely serve the same purpose.
In fact, classification schemes are likely to have the most pre-
dictive value when data from multiple platforms are combined.
Therapeutic choices will be specifically targeted at the altered
pathways that define cancer subgroups, and will expand greatly
as we develop a genome-wide catalog of cancer-related alter-
ations.Thus, genomics is not just increasing the pace of cancer
research, it is providing a completely new view of cancer cells,
allowing us to see the whole cell at once, rather than bits of the
cellular machinery in isolation.
Genomics will provide extremely detailed information and a
global framework for understanding complex patterns in cells.
Yet, as these complex datasets begin to emerge, so do the
problems of interpreting them. What is functionally significant
and what is noise? Which of the many differences between nor-
mal and tumor cells are the most promising molecular targets
for development? What are the defining features of a predictive
molecular classification scheme that can be reduced to clinical
use? What are the limitations of and sources of error from cur-
rently available genomic technology, and how can the scientific
community develop critical peer review of these data? And final-
ly, how can these data be made publicly available, enhancing
their usefulness by allowing data mining by individuals of
diverse viewpoints and interests? Addressing these problems,
and thereby taking full advantage of the power of genomics, will
require the implementation of high throughput validation
schemes, new paradigms for drug development, close collabo-
ration between laboratory scientists and clinicians, and the
development of standard nomenclature, data sharing formats,
and quality-control measures—none of which exist at present.
The genomic tools discussed here may be considered in
three broad categories: those that identify regions of the
genome harboring genes altered in cancer, those that identify
mutations in specific genes, and those that identify genes with
an altered expression profile in cancer cells (Figure 1).
Proteomic tools, those needed to catalog global protein expres-
sion profiles and posttranslational modifications, pose largely
distinct and very complex challenges and are not considered
here.
Which genes are altered in cancer?
Cancer arises from an accumulation of mutations in a series of
genes over time. A panel of genes that are mutated in sequence
in colon cancer has been proposed (Kinzler and Vogelstein,
1996), and several genes, such as p53, have been evaluated
extensively in a wide range of tumor types.Yet to date, not one
human cancer has been completely described with a clear pic-
ture of all the genes altered in that cancer. In addition, even a
complete profile of the mutations in a given cancer represents
only a single point in time. Cancers evolve, mutations accumu-
late, and cellular heterogeneity develops, complicating the
analysis of tissue and accurate descriptions of individual
clones. Cancers may also develop in the setting of field defects,
where surrounding tissue, while appearing histologically nor-
mal, contains abnormalities that not only give rise to the tumor
but may affect its behavior. Even completely normal stroma
plays a role in tumor invasion and metastases, a effect that may
vary as a function of molecular defects in a cancer cell, adding
yet another layer of complexity to defining the alterations that
result in cancer.
Thus, while a more complete list of genes mutated in can-
cers may be assembled by screening more cancers, and para-
log searching, although limited (Futreal et al., 2001), may be of
some use in the selection of candidate genes for further study,
only whole genome approaches will provide a complete
description, unbiased by what we think should or might be
altered. An excellent example of a “post-genome” project
designed with this in mind is the Cancer Genome Project
(CGP), sited at The Sanger Center (Wellcome Trust Genome
Campus, Hinxton, UK). The CGP employs a high throughput
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mutation detection scheme to evaluate all human genes for
mutations in a large panel of tumors and cell lines with ultimate
goal of answering the question, “which genes are mutated in
human cancers?”
How many genes are altered in each cancer?
The exact number of alterations required for cancer to develop
into clinical disease is not known. It is likely that the number
varies by both type of alteration and tumor type, with estimates
ranging from a single translocation in a hematologic malignan-
cy, to three carefully selected mutations in an experimental
model (Hahn et al., 1999), and to probably many more in adult
solid tumors.
Providing a framework for considering which genes may be
altered in cancer cells, Hanahan and Weinberg (2000) pro-
posed six cellular capabilities they believe must be acquired by
cancer cells. These include growth signal autonomy, evasion of
apoptosis, insensitivity to antigrowth signals, sustained angio-
genesis, limitless replicative potential, and the capacity to
invade tissue and grow at metastatic sites. The means by which
these capabilities may be acquired vary mechanistically and
chronologically, and the number of mutations required to
acquire a specific capability varies as well, but the end result is
proposed as invariant. As such, this model allows for consider-
able flexibility in the absolute number of mutations that are
required for cancer to develop. For example, a p53 mutation will
both facilitate angiogenesis and evasion of apoptosis, a five-
step model if all other capabilities are acquired individually, but
in another cancer, several mutations may be required for the
acquisition of each capability, such that in some cases, many
mutations may be required before cancer fully develops.
The therapeutic implications of defining the number of dis-
ease-associated mutations in a cancer cell also remain
unknown. One might expect that if a single mutation confers all
six necessary capabilities of cancer development, then this
tumor should be easy to treat if the appropriately targeted thera-
peutic agent can be delivered. But does this ever occur? And
even if it does, is this reasoning correct? Can a single agent be
expected to reverse all six properties? Do all six cancer-related
capabilities need to be reversed, or is reversing one or two of
them enough to eradicate the tumor? Again, attempts to answer
these questions are unsupported by analysis of even a single
human cancer in which one can confidently enumerate and
define the critical cancer-causing mutations, and even a com-
plete list of all mutations in a given cancer may be too simplistic.
Considering mutations in the context of transcriptional and epi-
genetic changes and the surrounding tissue also may be
required, and is the real promise of genomics—a comprehen-
sive understanding of the complex cellular and host environ-
ment of cancer cells created by combining multiple platforms
and analytic approaches.
How are genes altered in cancer?
Understanding mechanisms by which genes are altered is
central to choosing analytic techniques and is probably neces-
sary to develop diagnostic and therapeutic strategies. Base
substitutions can activate proto-oncogenes (often by enabling
ligand-independent proliferative signaling) and inactivate tumor
suppressor genes, sometimes producing dominant negative
effects. Large genomic deletions, small intragenic insertions
and deletions, and promoter silencing by methylation or other
epigenetic effects are primarily relevant to tumor suppressor
genes. These changes may result in complete absence of pro-
tein, unstable or absent transcripts, a truncated but inactive
product, or, as noted above, a truncated or mutated protein that
may sequester wild-type protein or act as a competitive inhibitor
of wild-type function.
In considering the significance of mutations in putative
tumor suppressor genes, and thus their value as therapeutic
targets, it is normally assumed that Knudsen’s two hit hypothe-
sis applies (Knudsen, 1971). However, recent work suggests
that in some cancer susceptibility syndromes, as well as in spo-
radic tumor formation, haploinsufficiency also may be impor-
tant. Murine models of haploinsufficiency include monoallelic
loss of PTEN in the promotion of prostate cancer progression
(Kwabi-addo et al., 2001) and Smad4/DPC4 (+/−) mice with
gastric polyps that progress to carcinoma in situ without loss of
the remaining Smad4/DPC4 allele (Xu et al., 2000). Studies of
P27KIP1 in acute lymphoblastic leukemia provide some evi-
dence for haploinsufficiency in human cancers (Fero et al.,
1998), but the identification of germline mutations CBFA2 in
familial platelet disorder (FPD) provides perhaps the best evi-
dence that gene dose is important for tumor suppression (Song
et al., 1999). Individuals with FPD are heterozygous for
germline mutations in CBFA2, with defects in both platelet num-
ber and function, despite the presence of one normal,
expressed allele. Acute leukemias develop in 30%–50% of
mutation carriers, without loss of wild-type CBFA2 expression.
These effects should come as no surprise, given the numerous
examples of gene dosage effects on the development and fit-
ness of organisms, with trisomies and contiguous gene deletion
syndromes being well-described examples. However, they do
suggest that the common practice of dismissing candidate
Figure 1. Genomic technologies for the analysis of cancer
Direct sequencing and heteroduplex detection provide the most accu-
rate and flexible approaches to high throughput analysis of small intra-
genic mutations. Array comparative genomic hybridization (CGH) is the
technology most amenable to identifying larger deletions and amplifica-
tions, but once identified, these regions must be analyzed to determine
which genes have an effect on cancer development. Expression profiling
will identify up- and downregulated transcripts that may occur in the
absence of detectable DNA mutations. However, no technology has yet
evolved as the clear solution to cataloging global methylation profiles.
Downregulated transcripts detected using expression profiling may in turn
be evaluated for promoter methylation, but this two-step process is cum-
bersome and will not identify effects of methylation other than gene silenc-
ing.
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tumor suppressor genes when mutations are only identified in
one allele may result in missing important molecular targets,
and that we should pay close attention to transcripts with
reduced but not absent expression levels.
Gene amplification (another example of gene dose effect)
often affects growth factor receptor genes and gives tumor cells
a selective advantage by enhancing response to levels of ligand
that would not otherwise trigger proliferation.While amplification
may generate many gene copies, data from studies of the MET
oncogene in papillary renal carcinoma suggest that the com-
bined effect of an activating point mutation coupled with only a
small increase in copy number (3–4 copies per cell) may also
play an key role in transformation (Fischer et al., 1998). Finally,
oncogenes may be created by balanced chromosomal translo-
cations, often juxtaposing the functional domain of a transcrip-
tion factor with heterologous sequences that remove normal
constraints on signaling, such as the bcr-abl oncogene created
by the 9:22 translocation in chronic myelogenous leukemia.
While defining individual alterations is clearly important,
combining data from multiple platforms is central to placing
genetic alterations in context. As one example of tumor sup-
pressor mutations that depend on cellular context, p53 and
BRCA1 mutations are cooperative in tumorigenesis, and a p53
mutation, or one in a related checkpoint, may be required for the
tumorigenicity of BRCA1 mutations (Bertwistle and Ashworth,
1998). This may be because loss of BRCA1 function with intact
checkpoints leads to cell death, but in the absence of normal
checkpoint function, cells survive and catastrophic genome
instability develops.Yet even pairwise gene interactions provide
a very simplistic example. Considering the thousands of genes
that differ in expression between normal and tumor cells, it is
likely that multiple interactions at each level of analysis are rele-
vant to considering the biologic behavior of a cancer. One
approach to looking at gene mutations in context is to evaluate
the expression profile of a cancer from the standpoint of known
mutations in that tumor, yet considering the number of genes
that are mutated in various cancers and the enormous number
of possible transcriptomes in human can-
cer, even this straightforward approach is
a daunting task. Full characterization of
tumor cells will require data sharing
between investigators to generate sam-
ple sets with adequate statistical power
and will likely produce models that need to be further refined
with the addition of data from other genomic platforms, again
increasing the complexity of the analysis.
Despite the complexities that develop when exponentially
increasing the amount of data that describe a tumor, another
advantage of integrating more than one platform is the ability
to strengthen functional inferences. Using genome-wide
expression profiling coupled with “interactome” data from
Saccharomyces cerevisiae found in public databases, Vidal and
colleagues have shown that genes with similar expression pro-
files are more likely to encode interacting proteins (Ge et al.,
2001). While clustering transcripts with similar expression pat-
terns suggests placement of gene products into identical or
related pathways, the integration of genome-wide protein-pro-
tein interaction data with expression analysis enhances the
inferences that can be made, as well as the resolution of those
inferences. In this case, the combination of two datasets sug-
gests where in a pathway proteins may act, and exact points at
which cellular pathways intersect.
High resolution detection of chromosomal aberrations
Array comparative genomic hybridization 
Array comparative genomic hybridization (CGH), while not use-
ful for detection of small intragenic mutations, is extremely well
suited to high-throughput, whole genome detection of chromo-
somal gains and losses at high resolution (Figure 2). Further
streamlining this methodology, the availability of the draft
human genome sequence means that chromosomal loci with
copy number variation can be linked to the human genome
sequence directly and immediately by the map location of
clones on the array, and a list of candidate genes generated
very quickly. The initial study used arrayed BAC and P1 DNA
from chromosome 20 with a mean spacing of 3 Mb (Pinkel et al.,
1998) and demonstrated the feasibility of detecting both gains
and losses with single copy sensitivity using array CGH. Brown
and Botstein subsequently demonstrated the utility of cDNA
arrays for array CGH, which have the benefit of targeting analy-
Figure 2. Array-based comparative genomic
hybridization
First, tumor DNA is prepared and labeled with
Cy3 (green) and cohybridized to an array made
up of genomic clones with normal genomic
DNA, labeled with Cy5 (red). A laser scanner
reads spot intensities for each dye separately,
and then the images are overlain to obtain the
combined image. Spots appearing yellow when
both tumor and normal DNA contain equal
copy number DNA at the locus represented by a
specific clone. Using this color scheme, ampli-
fied chromosomal regions appear green and
deleted regions appear red. However, in reality,
the relative intensities must be normalized to
determine signal intensity representing diploid
copy number, then the ratio of Cy3:Cy5 adjust-
ed for unequal fluorescence, and finally ratios of
normal to tumor DNA for each spot can be com-
puted and plotted for visual analysis.
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ses at expressed genes (Pollock et al., 1999). However, experi-
ence in several labs suggests that arrays constructed from large
insert genomic clones result in more uniform hybridization kinet-
ics than those made up of cDNAs, reducing the difficulty of nor-
malizing signals. The current sensitivity of array CGH is limited
largely by the spacing of genomic clones used to construct the
arrays, but a BAC library with an average spacing of 1–2 Mb
across the genome is now publicly available and the entire min-
imum tiling path of BAC clones is expected to become a public
resource shortly (http://www.ncbi.nlm.nih.gov/genome/clone/
ordering.html).
With adequate attention to normalization, array CGH is
amenable to detection of both homozygous and hemizygous
deletions that similarly may mark the location of tumor suppres-
sor genes, defects previously detectable only through labori-
ous analysis of individual candidate loci. Detection of large
homozygous deletions is likely to be particularly useful in the
identification of tumor suppressor loci—p16/MTS1 (Kamb et
al., 1994), SMAD4 (Hahn et al., 1996), PTEN (Li et al., 1997),
hSNF5/INI1 (Versteege et al., 1998), and RB (Friend et al.,
1986) all were mapped based on homozygous deletions.
Metaphase FISH, or modifications such as SKY (spectral kary-
otyping), remain the best way to identify translocations; howev-
er, neither of these are amenable to high throughput approach-
es. Chromosomal regions with frequent loss of heterozygosity
(LOH) are also thought to contain tumor suppressor genes.
Thus, even in the absence of a homozygous deletion, array
CGH is a powerful gene identification technique, as recently
illustrated by Gray and colleagues (Hodgson et al., 2001) with
an analysis of 84 murine islet cell tumors. The ratio of the CY3
and CY5 signal from genome regions with normal copy number
(two for autosomes and female sex chromosomes, one for each
sex chromosome in males) is used as a reference to define
regions of the genome with amplifications (copy number >2)
and deletions (<2). The analysis validated previous observa-
tions of recurrent LOH on mouse chromosomes 9 and 16, nar-
rowed the candidate regions as defined by genotypic mapping,
and identified previously unrecognized regions of recurrent
allelic imbalance in regions syntenic to human chromosomes
12p11-13, 16q24.3, and 13q11-32 (losses) and 20q13.2 and
1p32-36 (gains).
While examples of novel tumor suppressor genes identified
beginning solely with a region of LOH are hard to come by, there
are many examples of known tumor suppressor genes where
one allele is inactivated by a large deletion. These findings sug-
gest that the technology needed to find cancer-related genes in
large chromosomal deletions has been the limiting factor, not
that regions of LOH do not harbor tumor suppressor genes.
However, the genome instability and aneuploid nature of most
cancer cells poses difficulties for array CGH—reduction in copy
number from two to one is easily detectable with a robust nor-
malization scheme, but not all LOH follows this simple model.
Where there is mitotic recombination or chromosomal loss and
reduplication, copy number remains unchanged, but only a sin-
gle allele is present, and it may be a mutant allele.Other regions
of LOH may be undetectable because loss of the wild-type alle-
les occurs in the presence of multiple chromosome copies; thus,
the alleles may be present in ratios of 3:2 or 4:3, for example,
possibly of functional significance, but below the level of detec-
tion (reductions in dose of at least 50%).
Array CGH has two features that make it particularly
amenable to analysis of cancer cells. It is relatively insensitive to
normal cell contamination, and high quality probes may be pre-
pared from small amounts of archival material. Data from Gray
and colleagues (Hodgson et al., 2001) show that it is possible to
detect single copy changes in the presence of as much as 60%
contamination with normal cells. This is particularly important in
the analysis of tumors such as prostate and pancreatic cancer,
where the tumor often is so interdigitated with normal stroma
that even the use of laser capture microdissection may not be
adequate to produce pure populations of tumor cells. Normal
contamination also may occur from the lymphocytic infiltrates
found in many adult solid tumors. But unlike expression profil-
ing, contaminating normal cells should be invariant with respect
to the measurement being taken (i.e., genome copy number);
thus, if they do not compromise the ability to see copy number
change, they will not complicate the analysis.
The other attractive feature of array CGH is the success of
preparing high quality probes from small archival specimens.
The need for unfixed tissue is a very limiting aspect of expres-
sion analysis of cancer cells. The ability to use paraffin-embed-
ded tissue would greatly expand the number of specimens
available for expression analysis, but high quality RNA general-
ly is not extractable from archival material. However, array CGH,
requiring DNA probes, does not suffer from this limitation.
Pathology departments in most academic centers never discard
archival material, and most community hospitals have at least 5
years of paraffin-embedded tumor blocks in storage. With
appropriate approval, these blocks can be linked to medical
records, facilitating studies that correlate clinical outcomes with
patterns of chromosomal gains and losses.This may be particu-
larly informative for the cancers that arise in the setting of a field
defect, such as lung cancer due to carcinogen exposure, or
breast cancer, possibly related to multiple cycles of cellular pro-
liferation and regression.The resulting clonal expansion of mor-
phologically normal adjacent breast tissue with unsuspected
allelic imbalance may contain the earliest changes that initiate
transformation. The ability to separate and analyze this tissue
will be very informative in defining very early changes—an
application where array CGH has particular advantage. Finally,
many premalignant lesions can be fully analyzed by array CGH,
again because of the ability to use small amounts of archival
material. These lesions may be found alone or adjacent to inva-
sive cancers, and provide the best reagents to define the accu-
mulation of mutations during tumor development. They rarely
have been available for analysis because of their small size and
near impossibility of obtaining these lesions without fixative—
the latter due to the need for clinical pathologists to examine an
entire specimen rather than provide frozen tissue for research
studies.
Array CGH thus has enormous potential to speed the iden-
tification new cancer genes, evaluate sequential genetic
changes in tumor progression, and add to tumor classification
schemes. Current limitations are the availability of this technolo-
gy in only a few labs, the cost of commercial services (as much
as $1000 a sample for high resolution arrays), and the relative
lack of software to support the analyses. But the biggest
unknown is the utility of the data that will be generated. How
much will we miss buried in the heterogeneous and aneuploid
collections of cells that make up cancers? Will cell lines, which
have their own limitations, provide useful information, or will
there be so much noise from secondary genetic changes that
the false positive and negative rates will be prohibitive? Are
there sufficient numbers of small homozygous deletions to war-
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rant the analysis of extensive sample collections? And the
biggest question: will the multiple regions of recurrent LOH
described in the literature finally yield their long promised tumor
suppressor genes with enhanced mapping resolution? These
questions can only be answered as multiple investigators take
up this new approach to analyzing cancer genomes, but the
vast potential justifies a significant investment in this strategy.
High throughput mutation detection
Genomic sequencing 
High throughput genomic sequencing is one way to define the
genes that are mutated in cancer, but the technical hurdles are
significant, and the problem of sorting disease-associated
mutations from rare polymorphisms is enormous. Sequencing
genomic DNA detects the most common alterations in tumor
suppressor genes—base substitutions, small intragenic inser-
tions, and deletions—with high sensitivity, and provides data in
final form without an additional step. However, for most facilities,
high throughput sequencing is a wholly impractical considera-
tion for analyzing the genome of even a single cancer, due to
the effort and cost required for such an undertaking. In addition,
large deletions, rearrangements, and balanced translocations,
while theoretically detectable with extensive sequencing of
libraries prepared from individual tumors, will be missed, with
rare exception. Finally, epigenetic changes such as promoter
methylation are not detectable by sequencing without prior DNA
modification, such as bisulfite treatment, that converts non-
methylated cytosine to uracil (Clark et al., 1994). Thus, despite
the theoretical advantages of sequencing, it is not currently
practical for large-scale mutation analyses, leading to the con-
sideration of other strategies that are less labor intensive and
less costly.
Heteroduplex detection
Heteroduplex detection circumvents many of the difficulties
inherent in sequencing for mutation detection (Figure 3).
Several mutation detection techniques
are suited to genome-scale application,
including mismatch chemical cleavage
(Cotton et al., 1988), single strand confor-
mational analysis (Orita et al., 1989), and
denaturation-based methods (reviewed
in Fodde and Losekoot, 1994), but of
these, conformation sensitive gel elec-
trophoresis (CSGE) (Ganguly et al.,
1993) is particularly well suited to high
throughput analyses. Its simplicity makes
it amenable to multiplexing and automat-
ed detection of variants, recent modifica-
tions have adapted it for use with capil-
lary sequencers (Rozycka et al., 2000), and it is easily automat-
ed with standard robotics, further enhancing its applicability to
genome-wide mutation scans. CSGE also is more sensitive to
single base changes than techniques that rely on single strand
conformational changes, and the speed of both the analysis
and its interpretation provides significant advantages over
sequencing.
There are two principal limitations to genome-wide CSGE
analyses. First, genome-wide application of CSGE implies the
availability of intron-based primers for every gene, a resource
currently only available for a portion of the genome. In addition,
the sequence polymorphisms that plague direct sequencing
efforts also play havoc with CSGE if normal DNA from the same
individual is not available for heteroduplex formation. Rapidly
expanding polymorphism databases will aid in sorting disease-
assorted mutations from rare polymorphisms, but this adds both
uncertainty and an additional computational step. Nonetheless,
for most investigators, few of whom will want to screen an entire
genome for cancer-related mutations, CSGE is the easiest,
fastest, most sensitive mutation detection technique available.
Advances in mutation detection using microfabricated arrays,
further improvements in sequencing, and possibly advances in
mass spectrometry may eventually replace this approach, but
are not widely available at present.
Expression profiling
While cumbersome for gene discovery, expression profiling is
a powerful tool for describing cancer cells. It will identify thera-
peutic targets based on transcript level differences between
normal and malignant tissue, and is very useful in developing
molecular classification schemes that will ultimately drive ther-
apeutic choices (reviewed in Lockhart and Winzeler, 2000).
When used in experiments where cells are perturbed by a
specific exposure, expression profiling will define cellular
response, and in the setting of engineered mutations, it will
Figure 3. Heteroduplex-mediated mutation analysis
Heteroduplexes form following denaturation and
reannealing of fragments from mixed normal and
tumor DNA if the sequence varies between frag-
ments. In this case, the normal sequence contains
an adenine (A), which has been mutated in the
tumor DNA to a thymidine (T). The necessity of mix-
ing DNAs from normal and neoplastic tissue arises
because allelic loss, frequently the means by which
the remaining wild-type allele is lost, reduces a
somatic mutation to homozygosity, precluding for-
mation of heteroduplexes. Detection can be per-
formed on standard sequencing gels, automated
flat-gel sequencers, or capillary sequencers.
Once the genome is fully annotated,
arrays are expanded to include all human
genes, enhanced analytic techniques
improve the ability of expression arrays to
detect small differences, and databases
to compare arrays between investigators
are in place, it is unlikely that SAGE will
be useful. Array-based transcriptional
profiling is more amenable to large scale
projects, considerably less time-consuming, and certainly more
widely used. However, these advances will take several years,
and for that time, SAGE remains a valuable and viable tool.
Expression arrays 
Expression arrays are constructed of thousands of DNAs either
spotted or synthesized onto glass slides (Lockhart et al., 1996;
Schena et al., 1995). The DNAs may be collections of short oli-
gos (e.g., 25mers), longer oligos (e.g., 60mers), or cDNAs of
variable length. Spotted arrays employ fluorescent dye detec-
tion, commonly using a cohybridization strategy with Cy3-
labeled cRNA from the test sample and a Cy5-labeled refer-
ence sample providing an intensity ratio, and thus a measure of
relative expression. In contrast to array CGH, however, where
the reference is genomic DNA, the optimal reference sample for
expression profiling would contain detectable levels of every
gene represented on the array within the linear range of the
detection system, and thus does not exist for large arrays. In
considering interpretation, relative expression differences of
2-fold or greater are generally considered significant, with less-
er changes thought more likely to represent experiment varia-
tion.
However, while the use of reference samples and arbitrary
significance thresholds for the interpretation of spotted arrays is
a widely accepted experimental design, recent data suggest
this design has multiple disadvantages and in fact may lead to
erroneous conclusions (Jin et al., 2001). Perhaps most signifi-
cantly, this design is inadequate for direct quantitative analysis
of absolute transcript levels—essential if data from different
experiments and labs are to be analyzed collectively. Jin et al.
(2001) also provide convincing evidence that the common prac-
tice of setting arbitrary threshold ratios to assign significance
has no basis in either biologic reality or in statistical theory.
Without the use of a reference sample, which they point out pro-
vides no information of biologic interest, they evaluated expres-
sion differences that vary by age, sex, and strain in D.
melanogaster. In these experiments, repetitive pairwise com-
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add to the development of contextual frameworks. Finally, dif-
ferentially expressed transcripts identify genes silenced by
methylation or other epigenetic mechanisms, as well as genes
overexpressed in the absence of gene amplification. Both
SAGE (Serial Analysis of Gene Expression) (Velculescu et al.,
1995) and array-based expression profiling have been used to
this end.
SAGE
SAGE (Figure 4) straddles the boundaries between gene dis-
covery, mutation detection, and expression profiling
(Velculescu et al., 1995), based on the principles that a 10 bp
sequence tag will uniquely identify most human transcripts
(assuming ~100,000 transcripts derived from ~35,000 unique
genes) and that sequencing of SAGE libraries accurately
reflects transcript number. Dismissed by some as prohibitively
time-consuming, SAGE does have advantages. Library analy-
sis can be automated and the analyses are amenable to high
throughput approaches. In addition, SAGE libraries may be pre-
pared from very small numbers of cells, facilitating application
to premalignant tissue and small tumors. There is some indica-
tion that these “micro-SAGE” libraries are more representative
than cRNA subjected to linear amplification for array analysis.
(Ishii et al., 2000; Neilson et al., 2000) In a head to head com-
parison between SAGE and array-based expression profiling,
there was excellent correlation in highly differentially expressed
transcripts, and some evidence that SAGE is more sensitive in
measuring low abundance transcripts and small differences in
expression, both of which are likely be biologically significant.
SAGE also has the advantage of being useful for gene discov-
ery, a limitation of expression arrays that are comprised only of
known genes or ESTs. This feature of SAGE is illustrated by a
recent publication of the PRL-3 tyrosine phosphatase as a gene
implicated in colon cancer metastasis (Saha et al., 2001). This
observation was missed in other labs, not because of subtle
expression differences but because PRL-3 is not represented
on all commercially available expression arrays.
Figure 4. Preparation of a SAGE library
Data are generated from specific SAGE libraries
as follows: (1) cDNA is prepared from tissue or
cells using biotinylated dTTP; (2) cDNA is bound
to streptavidin beads and cleaved into short
fragments with a restriction enzyme recognizing
a frequent four base pair sequence; (3) linkers
with a type IIS restriction site are added, allowing
cutting 1520 bp from the IIS site and resulting in
incorporation of 1012 bp of 3′ cDNA into the
linker fragment; (4) the fragments are concate-
merized and cloned into a sequencing vector
(allowing serial analysis of 3035 transcripts per
sequencing run); and (5) the SAGE library is
sequenced, providing a comprehensive and
quantitative picture of expressed genes without
the need for any previous sequence data.
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parisons with age remaining the constant variable provided
maximal power to detect age effects while still allowing for an
analysis of the other two variables. Thus, two strains (Oregon
[O] and Samarkand [S]), two ages (1 week and 6 weeks), and
both sexes (M and F) were compared directly in pairs:
OF1–OF6, OM1–OF6, SF1–SF6, and SM1–SM6. Each array
was repeated six times, two of the six replicates with a dye
swap. ANOVA, a variance analysis standard in statistical genet-
ics, was employed for analysis. The findings are remarkable,
and call into question much of the currently published array
data. First, dye swapping had a marked effect, with multiple
examples where opposite conclusions would be reached
depending on the choice of dye (Cy3 or Cy5) for pair members.
Second, the rigorous statistical analysis provided proof that
arbitrary thresholds are not useful for assigning significance.
After adjusting for both stochastic and biased variance, differ-
ences as low as 1.2 fold remained highly significant, and differ-
ences as great as 10-fold were dismissed as artifact. These
data also highlight the fact that an arbitrary reference sample
can bias a study toward unwarranted conclusions and limit
power to detect changes in genes that are expressed at particu-
larly high or low levels in the reference, as well as constrain data
sharing between experiments that have not employed the same
reference sample. These elegant analyses strongly suggest
that we should rethink the widely used experimental design
employing reference samples and arbitrary significance thresh-
olds, replacing this design with one that allows definition of
absolute units of expression, rather than ratios, and is most suit-
ed to the research question at hand. Thus, if looking for small
effects, all pairs should be selected around the variable likely to
have the least impact (age, in these experiments), as the power
to see the effects of a specific variable is maximized if that vari-
able remains constant in all pairwise comparisons. If the aim is
to compare the effects of an exposure to a panel of different
cells or tissues, then a looping or randomized pair design pro-
vides the best means of comparison.
Oligonucleotide arrays manufactured with twenty 25mers
representing each gene on the array—10 perfect match
sequences and 10 with a mismatch at the middle position—
(Affymetrix, Inc) do have the advantage over spotted arrays of
having been designed for use without a reference sample. The
multiple oligomers provide some measure of replication, as tar-
get cRNA binds each independently, allowing an assessment of
sensitivity and specificity; e.g., the composite signal generated
from 9 perfect matches and 1 mismatch is weighted more heav-
ily than a signal from 3 perfect matches and 6 mismatches.
However, this design still does not correct for stochastic experi-
mental variation nor bias in hybridization to specific probes, and
thus does not address the problem of reliably detecting small
differences between samples. The cost of these arrays con-
strains the application of multiple replicates, and leaves the val-
idation of marked changes in individual genes to conventional
approaches. In addition, genes that are not expressed in at
least modest levels, and thus called “present,” cannot be evalu-
ated at all in comparisons, and as with all arrays, incomplete
genome annotation remains a significant limitation. Finally, the
corporate policy of not providing investigators with the actual
oligonucleotide sequences on the array completely eliminates
the possibility of fully interpreting the primary data.
A potential technical improvement in the sensitivity and
specificity of expression profiling (Hughes et al., 2001) may
come from the use of single 60mers deposited using inkjet tech-
nology. This eliminates the need for masking in manufacture,
reducing cost and greatly increasing flexibility. With careful
selection of oligonucleotide sequence, this platform reportedly
detects transcripts present at 0.1 copies per cell and discrimi-
nates any transcript in the genome that differs from another by
five or more base pairs in the representative 60mer. The sensi-
tivity, specificity, and flexibility of this system, particularly if used
with the rigorous statistical analysis suggested by Jin el al.
(2001), may make these arrays the best platform produced to
date; however, they have yet to be made generally available so
that they can be tested in academic labs.
Much has been made of the problems of data overload and
the lack of hypothesis-driven research associated with expres-
sion profiling. However, neither of these criticisms accurately
reflects either the power or the current limitations of this tech-
nology.Management of data derived from expression profiling is
relatively straightforward—it is the lack of databases to aid in
the generation of hypotheses and the extraction of biologically
meaningful conclusions from the data that prove most problem-
atic. Most investigators are experts in specific areas—cell cycle
regulation, apoptosis, homeobox genes, and so on. How then
can any one investigator wisely use data from experiments that
provide information on virtually every cellular pathway? A badly
needed resource is a database placing genes in the context of
interconnected pathways, organized by relationships and pro-
viding links to relevant literature. Several databases for model
organisms, such as Flybase, Wormbase, and Saccharaomyces
Genome Database (SGD) incorporate sequence data, expres-
sion analyses, regulatory data, pathways, and phenotype.
KEGG provides some mammalian pathway information, but no
comprehensive database exists for either mice or humans.
Links between these organism-specific databases, allowing
comparative analysis, would add further to their value.
Another resource that is badly needed is a collection of
expression profiles for public data mining. Steps toward imple-
menting such a database have been taken by the Microarray
Gene Expression Database group, who suggest minimal cri-
teria for data in such a public repository (Brazma et al., 2001).
However, we are far from the implementation of standardized
terms format and content, means and agreements to deposit
primary data, and even the ability to critically peer review global
expression profiling data. It is incumbent on all investigators
using this technique to contribute to these efforts to make their
data available after publication (as is expected of sequence
data) and in so doing, assist in creating a rigorous scientific
standard for using and evaluating these data.
One example of the usefulness of large expression data-
bases is illustrated in the use of expression profiling to assign
function to uncharacterized open reading frames (ORFs) and to
identify novel drug targets (Hughes et al., 2000). In this study,
expression profiles from uncharacterized ORFs were compared
to a (private) compendium of expression profiles from 300
known yeast mutants using a computational fingerprinting tech-
nique. Data from the mutant profiles first were clustered to
define prominent expression patterns, identifying mutants with
similar profiles and sets of coregulated genes. Comparing pro-
files from ORFs of unknown function to known mutants placed
the uncharacterized genes in cellular pathways that directed
subsequent biochemical experiments, none of which would
have been assigned in a standard phenotype screen. These
clusters were resilient to removing all transcripts encoding pro-
teins with known function or their close paralogs, illustrating
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independence from knowledge of specific transcripts and a
complete genome profile. In addition, none of the uncharacter-
ized ORFs assigned into known pathways were up- or downreg-
ulated by more than 2-fold in any of the 300 compendium pro-
files, nor did profile assignments change when all transcripts
with greater then 1.5-fold changes were masked, again high-
lighting the need for increased sensitivity from arrays.
Expression profiling is the most widely used genomic tech-
nology in current use. It has dramatically increased the amount
of data recovered from single experiments and has initiated the
process of molecular classification of tumors. Examples include
breast cancers assigned to distinct categories based on pre-
sumed cell of origin within the breast (Perou et al., 2000),
melanoma subtype suggested by expression of genes impor-
tant in motility and invasion (Bittner et al., 2000), non-Hodgkin
lymphoma clustered to more accurately reflect prognosis
(Alizadeh et al., 2000), and the illustration that cancers that
arise from a known event, such as a germline BRCA1 or
BRCA2 mutation (Hedenfalk et al., 2001), can be separated
from a more heterogeneous group of sporadic cancer-based
expression profiles. However, all these clustering schemes
employed relative small numbers of tumors, and at least in the
case of lymphoma, marked expansion of the sample set yielded
far too many tumor subsets to be clinically useful. The
melanoma subtypes were derived from a set of 31 cancers with
a uniformly bad prognosis, and the categories defined by the
clusters did not correlate at all with extensively validated prog-
nostic indicators such as depth. Are we correctly interpreting
what these clusters are telling us? Can we exclude the possibil-
ity that these clusters are not a measure of factors such as nor-
mal cell admixture (clearly seen in the breast cancer profiling
scheme) or sample handing differences? What are the sources
of error and how might the clusters reflect this—particularly in
light of the recent illustration of dye effect? How do we best elim-
inate predictors that solely reflect tissue of origin, and incorpo-
rate known clinical predictors to develop clustering schemes
that are truly reflective of biological behavior and accurately
reflect treatment response? While there is little doubt that
molecular classification schemes that accurately predict tumor
behavior will arise from expression profiling and other genomic
platforms, it is clear that many more tumors will need to be ana-
lyzed, some aspects of the current clinical schemes will need to
be incorporated, and modifications will continue as treatment
response is added to the clustering as well.
Detection of epigenetic changes
Global methylation screens
Global methylation screens, still fraught with technical prob-
lems, are being developed to construct genome-wide profiles of
CpG island methylation. Evidence that promoter methylation
may be important in cancer comes from studies of methylation
as a means of inactivating tumor suppressor genes, yet a tumor
suppressor gene inactivated in cancer only by promoter silenc-
ing has yet to be confirmed, nor is there an example of a proto-
oncogene activated only by promoter demethylation. The
absence of such examples may be due to the limitations of a
candidate gene approach, which even in the largest reported
series—12 genes in more than 600 primary tumors (Esteller et
al., 2001)—barely scratches the surface of what could be an
average of 600 aberrantly methylated CpG islands in human
cancer (Costello et al., 2000). It also could be that genes that
cause cancer are rarely, if ever, altered only by methylation. If
the latter is true, then we will not miss oncogenes and tumor
suppressor genes, and thus important targets, in the absence of
whole genome methylation data. However, if, as seems plausi-
ble, the means by which genes are altered can be exploited in
developing therapeutic approaches, then these data may be
extremely useful in developing drugs to reactivate silenced
tumor suppressor genes.
Several global methylation assays are under development,
including a high-density array of CpG islands (Yan et al., 2001).
However, the approach requires a tedious, somewhat tricky
sample preparation, and the current array of about 8,000 CpG
islands is a significant underrepresentation of the estimated
45,000 that may be in the genome (admittedly not all of which
are upstream regulatory elements of transcribed genes)
(Costello et al., 2000). Restriction landmark genomic scanning
(RLGS), a two-dimensional (2D) gel approach utilizing the
methylation sensitivity of NotI sites for differential end-labeling
of digested fragments prior to electrophoretic separation
(Costello et al., 2000), shows promise as well. However, a limit-
ed number of CpG islands can be analyzed simultaneously with
gel-based technology (1,184 in this study), and the image
analysis of 2D gels with thousands of spots is time-consuming
and subject to error. Possibly the most significant observation
made to date using RLGS is that methylation profiles appear to
be tissue type-specific, i.e., tumors can be clustered based on
RLGS into groups that correlate with the tissue from which they
arose. Whether it is a recapitulation of our current histological
scheme or a more predictive analysis remains to be seen.
A number of other techniques, including methylation-sensi-
tive arbitrarily primed PCR (Gonzalgo et al., 1997), methylated
CpG island amplification (Toyota et al., 1999), and construction
of a murine model with inducible DNA methyltransferase1
(DNMT1) (Jackson-Grusby et al., 2001) have been described to
investigate global promoter methylation changes. The first two
techniques detect promoter methylation directly, while the later
is a clever example of the use of expression profile changes to
detect promoters that have been silenced by methylation. In this
model, profiles are generated before and after induction of
DNMT1, with upregulated genes as candidates for having
undergone demethylation, and thus tagged as methylated in the
preinduction state. Breeding DNMT1 inducible mice to gene-
specific tumor models and cataloging the genes methylated in
those tumors using expression profiling after DNMT1 induction
should yield interesting data on gene-specific methylation
changes in cancer and simultaneously evaluate the potential for
methylase inhibitors as cancer therapeutics. As no one tech-
nique yet has overcome the problems associated with determin-
ing global methylation profiles, this is a critical area for technical
development and analysis.
Therapeutic successes with molecular targets
The use of cytotoxic agents has led to significant successes
over the past fifty years in the treatment, and sometimes cure,
of cancer. Childhood acute leukemias and nonseminomatous
germ cell tumors were once uniformly fatal, but multidrug regi-
mens result in cure rates that now approach 80% for some sub-
types, including widely metastatic disease in the case of testes
cancer. Some adult leukemias and lymphomas are curable, and
combination chemotherapy for early breast cancer reduces
recurrence rates, but we remain unable to uniformly prevent
development of metastatic disease from most solid tumors in
both children and adults. Even when curative, many treatments
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are associated with significant toxicity. In order to significantly
improve on the current state of cancer treatment, it is essential
that we develop therapies designed to specifically reverse the
acquired capabilities that drive cancer cells. This approach,
when sufficiently refined, not only should be effective in curing
cancers, but should do so with limited toxicity. Several examples
of cancer treatments based on molecular targets are already
being used to treat patients, and they illustrate the principle that
understanding the specific genetic defect that creates a molec-
ular target is essential to the success of these agents.
The use of amplified proto-oncogenes as molecular targets
is exemplified by herceptin, a blocking antibody directed at
HER2/neu, a transmembrane tyrosine kinase growth factor
receptor amplified in approximately 30% of breast cancers
(reviewed in Harari and Yarden, 2000). While some toxicity
occurs in normal cells with low levels of HER2/neu expression,
the large differential in receptor number between normal and
tumor cells gives a significant therapeutic index.Yet, why is her-
ceptin only marginally effective in treating breast cancer?
Presumably, high levels of HER2/neu expression are only part
of the picture, and modulation of receptor expression further
limits response. Both problems may be solved by applying
genomic approaches to understand what other cellular path-
ways are disrupted in these cells, as well as elucidating the
mechanisms that lead to herceptin resistance. The epidermal
growth factor receptor (EGFR) is another molecular target com-
monly overexpressed in human tumors. ZD1839 (Iressa) is a
quinazoline tyrosine kinase inhibitor selective for EGFR current-
ly in clinical trials. Growth inhibition by ZD1839 occurs with
dephosphorylation of EGFR, HER2, and HER3, dissociation of
HER3 from PI(3)-kinase, and downregulation of Akt (Moasser
et al., 2001).
Finally, the most recent example derived from molecular tar-
geting is that of STI571, an Abl kinase inhibitor that targets the
fusion protein formed by t(9; 22) (the Philadelphia chromosome)
found in most cases of chronic myelogenous leukemia (CML)
(Nowell and Hungerford, 1960). In Bcr-Abl, the coiled-coil
domain of Bcr oligomerizes, leading to autophosphorylation
and thus activation of the Abl kinase domain (McWhirter et al.,
1993). In addition, the c-Abl DNA binding domain is replaced by
Bcr sequences that mediate cytoplasmic sequestration, result-
ing in a form of Abl unable to induce apoptosis (Wang and
Vigneri, 2001). Bcr-Abl thus has all the mitogenic activity of
c-Abl, mediated through the Ras-Raf-ERK, JAK-STAT, and
PI(3)kinase pathways, and none of the apoptotic activity of
nuclear c-Abl, mediated through p73 (reviewed in Hunter and
Blume-Jensen, 2001).
The success of treating CML with STI57 demonstrates the
value of understanding the mechanism producing the cancer-
causing mutation. STI 571 not only inhibits kinase-dependent
growth signals but also induces apoptosis, because cytoplas-
mic retention of Bcr-Abl is partially dependent on the kinase
activity of Abl (Druker et al., 1996; Horita et al., 2000). Thus,
STI571 induces nuclear import of Bcr-Abl. This dual effect of
STI571 raises the possibility of combining STI571 with a
nuclear export inhibitor to enhance effectiveness and circum-
vent resistance (Wang and Vigneri, 2001). Also of significance
in considering the future of targeting therapy is the dramatic effi-
cacy of STI571 in treating tumors with related kinase mutations.
Gastrointestinal stromal tumors (GIST), rare cancers with
extremely rapid growth rates and a dismal prognosis, often have
a mutation in c-kit, and respond dramatically to STI571
(Joensuu et al., 2001). These data are encouraging not only for
patients with this rare disease, but also because they suggest
that limited targets may need to be exploited, with activity of
specifically targeted agents extending to other related mole-
cules and thus active in multiple tumor types.
While drugs designed to specifically inhibit amplified, over-
expressed, or activated proto-oncogenes are beginning to
appear in the clinic, therapeutic agents that replace absent
tumor suppressor gene activity are more troublesome, due to
the complexities of functionally replacing an absent protein.
Methylase inhibitors are being tested clinically, and show some
promise as antitumor agents. Given that newly synthesized
DNA must be actively methylated to maintain imprinting and
tumor-specific methylation patterns, methylase inhibitors may
be useful in reactivating tumor suppressor genes. However,
methylation is thought to occur as a result of only a few
enzymes, and gene-specificity of methylation in cancer is not
well understood. Thus, these agents may not circumvent the
problems of toxicity in the absence of a specific target and lack
of tumor-specificity unless incorporated into a targeted drug
delivery systems.
Conclusion
Innovations in microfabrication and capillary sequencing tech-
nology, coupled with a draft of the human genome sequence,
have led to the development of several high throughput
approaches to describe the genetic and epigenetic changes
that contribute to cancer. While many cancers have yet to be
even partially analyzed, and questions critical to designing suc-
cessful therapeutics remain unanswered, it is now possible to
envision a time when molecular phenotyping and targeted, indi-
vidualized therapies that cure cancer will be a commonplace
reality. Genomics is critical to these efforts, not only because it
has exponentially increased data collection, but because it pro-
vides the opportunity not afforded by conventional approaches
to see cancer from a global perspective, with specific alterations
placed in context. Despite the current limitations, it is this fea-
ture of genomics that will enable a fundamental change in our
understanding of cancer and thus our ability to cure patients.
References
Alizadeh, A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A.,
Boldrick, J.C., Sabet, H., Tran, T., Yu, X., et al. (2000). Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling. Nature 403,
503–511.
Bertwistle, D., and Ashworth, A. (1998). Functions of the BRCA1 and BRCA2
genes. Curr. Opin. Genet. Dev. 8, 14–20.
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M.,
Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., et al. (2000). Molecular
classification of cutaneous malignant melanoma by gene expression profil-
ing. Nature 406, 536–540.
Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P.,
Stoeckert, C., Aach, J., Ansorge, W., Ball, C.A., Causton, H.C., et al. (2001).
Minimum information about a microarray experiment (MIAME)-toward stan-
dards for microarray data. Nat. Genet. 29, 365–371.
Clark, S.J., Harrison, J., Paul, C.L., and Frommer, M. (1994). High sensitivity
mapping of methylated cytosines. Nucleic Acids Res. 22, 2990–2997.
Costello, J., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., Robertson, G.P.,
Gao, X., Wright, F.A., Feramisco, J.D., Peltomaki, P., Lang, J.C., et al. (2000).
Aberrant CpG-island methylation has non-random and tumor-type-specific
46 CANCER CELL : FEBRUARY 2002
P R I M E R
patterns. Nat. Genet. 24, 132–138.
Cotton, R., Rodrigues, N.R., and Cambell, R.D. (1988). Reactivity of cyto-
sine and thymine in single base-pair mismatches with hydroxylamine and
osmium tetroxide and its application to the study of mutations. Proc. Natl.
Acad. Sci. USA 85, 4397–4401.
Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning,
S., Zimmermann, J., and Lydon, N.B. (1996). Effects of a selective inhibitor
of the Abl tyrosine kinase on the growth of Bcr-Abl postive cells. Nat. Med.
2, 561–566.
Esteller, M., Corn, P.G., Baylin, S., and Herman, J.G. (2001). A gene hyper-
methylation profile of human cancer. Cancer Res. 61, 3225–3229.
Fero, M.L., Randel, E., Gurley, K.E., Roberts, J.M., and Kemp, C.J. (1998).
The murine gene p27Kip1 is haplo-insufficient for tumour suppression.
Nature 396, 177–180.
Fischer, J., Palmedo, G., von Knobloch, R., Bugert, P., Prayer-Galetti, T.,
Pagano, F., and Kovacs, G. (1998). Duplication and overexpression of the
mutant allele of the MET proto-oncogene in multiple hereditary papillary
renal cell tumours. Oncogene 17, 733–739.
Fodde, R., and Losekoot, M. (1994). Mutation detection by denaturing gra-
dient gel electrophoresis (DGGE). Hum. Mutat. 3, 83–94.
Friend, S., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M.,
Albert, D.M., and Dryja, T.P. (1986). A human DNA segment with properties
of the gene that predisposes to retinoblastoma and osteosarcoma. Nature
323, 643–646.
Futreal, A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and
Stratton, M.R. (2001). Cancer and Genomics. Nature 409, 850–852.
Ganguly, A., Rock, M.J., and Prockop, D.J. (1993). Conformation-sensitive
gel electrophoresis for rapid detection of single-base differences in double-
stranded PCR products and DNA fragments: evidence for solvent-induced
bends in DNA heteroduplexes. Proc. Natl. Acad. Sci. USA 90,
10325–10329.
Ge, H., Liu, Z., Church, G.M., and Vidal, M. (2001). Correlation between
transcriptome and interactome mapping data from Saccharyomyces cere-
visiae. Nat. Genet. 29, 482–486.
Gonzalgo, M., Liang, G., Spruck, C.H., Zingg, J.M., Rideout, W.M., and
Jones, P.A. (1997). Identification and characterization of differentially-
methylated regions of genomic DNA by methylation-sensitive arbitarily-
primed PCR. Cancer Res. 57, 594–599.
Hahn, S., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T.,
Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., and
Kern, S.E. (1996). DPC4, a candidate tumor suppressor gene at human
chromosome 18q21.1. Science 271, 350–353.
Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks,
M.W., and Weinberg, R.A. (1999). Creation of human tumour cells with
defined genetic elements. Nature 400, 464–468.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell
100, 57–70.
Harari, D., and Yarden, Y. (2000). Molecular mechanisms underlying
Erb/HER2 action in breast cancer. Oncogene 19, 6102–6114.
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R.,
Meltzer, P., Gusterson, B., Esteller, M., Kallioniemi, O.P., et al. (2001).
Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344,
539–548.
Hodgson, G., Hager, J.H., Volik, S., Hariono, S., Wernick, M., Moore, D.,
Albertson, D.G., Pinkel, D., Collins, C., Hanahan, D., and Gray, J.W. (2001).
Genome scanning with array CGH delineates regional alterations in mouse
islet carcinoms. Nat. Genet. 29, 459–464.
Horita, M., Andreu, E.J., Benito, A., Arbona, C., Sanz, C., Benet, I.,
Prosper, F., and Fernandez-Luna, J.L. (2000). Blockade of the Bcr-Abl
kinase activity induces apoptosis of chronic myelogenous leukemia cells
by suppressing signal transducer and activator of transcription 5-depen-
dent expression of Bcl-xl. J. Exp. Med. 191, 977–984.
Hughes, T., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton, R.,
Armour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y.D., et al. (2000).
Functional discovery via a compendium of expression profiles. Cell 102,
109–126.
Hughes, T., Mao, M., Jones, A., Burchard, J., Marton, M., Shannon, K.,
Lefkowitz, S., Ziman, M., Schelter, J., Meyer, M., et al. (2001). Expression
profiling using microarrays fabricated by an ink-jet oligonucleotide synthesiz-
er. Nat. Biotechnol. 19, 342–347.
Hunter, T., and Blume-Jensen, P. (2001). Oncogenic kinase signaling. Nature
411, 355–365.
Ishii, M., Hashimoto, S., Tsutsumi, S., Wada, Y., Matsushima, K., Kodama, T.,
and Aburatani, H. (2000). Direct comparison of GeneChip and SAGE on the
quantitative accuracy in transcript profile analysis. Genomics 68, 136–143.
Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D.,
Csankovszki, G., Dausman, J., Lee, P., Wilson, C., Lander, E., and Jaenisch,
R. (2001). Loss of genomic methylation causes p53-dependent apoptosis
and epigenetic deregulation. Nat. Genet. 27, 31–39.
Jin, W., Riley, R.M., Wolfinger, R.D., White, K.D., Passador-Gurgel, G., and
Gibson, G. (2001). The contributions of sex, genotype and age to transcrip-
tional variance in Drosophila melanogaster. Nat. Genet. 29, 389–395.
Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., Andersson, L.C.,
Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S.,
Druker, B., and Demetri, G.D. (2001). Effect of the tyrosine kinase inhibitor
STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl.
J. Med. 44, 1052–1056.
Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K.,
Tavtigian, S.V., Stockert, E., Day, R.S., Johnson, B.E., and Skolnick, M.H.
(1994). A cell cycle regulator potentially involved in genesis of many tumor
types. Science 264, 436–440.
Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal
cancer. Cell 87, 159–170.
Knudsen, A. (1971). Mutation and cancer: statistical study of retinoblastoma.
Proc. Natl. Acad. Sci. USA 68, 820–823.
Kwabi-addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R.,
Greenberg, N., and Ittmann, M. (2001). Haploinsufficiency of the Pten tumor
suppressor gene promotes prostate cancer progression. Proc. Natl. Acad.
Sci. USA 98, 11563–11568.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J.,
Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain, breast, and
prostate cancer. Science 275, 1943–1947.
Lockhart, D., and Winzeler, E.A. (2000). Genomics, gene expression and
DNA arrays. Nature 405, 827–836.
Lockhart, D., Dong, H., Byrne, M.C., Follettie, M.T., Gallo, M.V., Chee, M.S.,
Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E.L. (1996).
Expression monitoring by hybridization to high-density oligonucleotide
arrays. Nat. Biotechnol. 14, 1675–1680.
McWhirter, J., Galasso, D.L., and Wang, J.Y. (1993). A coiled-coil oligomer-
ization domain of bcr is essential for the transforming function of the Bcr-Abl
oncoproteins. Mol. Cell. Biol. 13, 7587–7595.
Moasser, M., Basso, A., Averbuch, S.D., and Rosen, N. (2001). The tyrosine
kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and sup-
presses the growth of HER2-overexpressing tumor cells. Cancer Res. 61,
7184–7188.
Neilson, L., Andalibi, A., Kang, D., Coutifaris, C., Strauss, J.F., Stanton, J.A.,
and Green, D.P. (2000). Molecular phenotype of the human oocyte by PCR-
SAGE. Genomics 63, 13–24.
Nowell, P., and Hungerford, D.A. (1960). A minute chromosome in human
granulocytic leukemia. Science 132, 1497.
Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. (1989).
Detection of polymorphisms of human DNA by gel electrophoresis as single-
strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA 86,
2766–2770.
Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees,
CANCER CELL : FEBRUARY 2002 47
P R I M E R
C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. (2000).
Molecular portraits of human breast tumours. Nature 406, 747–752.
Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins,
C., Kuo, W.L., Chen, C., Zhai, Y., et al. (1998). High resolution analysis of
DNA copy number variation using comparative genomic hybridization to
microarrays. Nat. Genet. 20, 207–211.
Pollock, J., Westervelt, P., Kurichety, A.K., Pelicci, P.G., Grisolano, J.L., and
Ley, T.J. (1999). A bcr-3 isoform of RAR-alpha-PML potentiates the devel-
opment of PML-RAR-alpha driven acute promyelocytic leukemia protein
(PML) in tumor suppression. J. Exp. Med. 193, 521–529.
Rozycka, M., Collins, N., Stratton, M.R., and Wooster, R. (2000). Rapid
detection of DNA sequence variants by conformation-sensitive capillary
electrophoresis. Genomics 70, 34–40.
Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V.E., Rago, C., Croix,
B.S., Romans, K.E., Choti, M.A., Lengauer, C., Kinzler, K.W., and
Vogelstein, B. (2001). A phosphatase associated with metastasis of col-
orectal cancer. Science 294, 1343–1346.
Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995). Quantitative
monitoring of gene expression patterns with a complementary cDNA array.
Science 270, 467–470.
Song, W., Sullivan, M.G., Legare, R.D., Hutchings, S., Tan, X., Kufrin, D.,
Ratajczak, J., Resende, I.C., Haworth, C., Hock, R., et al. (1999).
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with
propensity to develop acute myelogenous leukaemia. Nat. Genet. 23,
166–175.
Toyota, M., Ho, C., Ahuja, N., Jair, K.W., Li, Q., Ohe-Toyota, M., Baylin,
S.B., and Issa, J.P. (1999). Identification of differentially-methylated
sequences in colorectal cancer by methylated CpG island amplification.
Cancer Res. 59, 2307–2312.
Velculescu, V., Zhang, L., Vogelstein, B., and Kinzler, K.W. (1995). Serial
analysis of gene expression. Science 270, 484–487.
Versteege, I., Sevent, N., Lange, J., Rousseau-Merck, M.F., Ambros, P.,
Handgretinger, R., Aurias, A., and Delattre, O. (1998).Truncating mutations
of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206.
Wang, J.Y., and Vigneri, P. (2001). Induction of apoptosis in chronic myel-
ogenous leukemia cells through entrapment of Bcr-Abl tyrosine kinase.
Nat. Med. 7, 228–234.
Xu, X., Brodie, S.G., Yang, X., Im, Y.H., Parks, W.T., Chen, L., Zhou, Y.X.,
Weinstein, M., Kim, S.J., and Deng, C.X. (2000). Haploid loss of the tumor
suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice.
Oncogene 19, 1868–1874.
Yan, P., Chen, C.M., Shi, H., Rahmatpanah, F., Wei, S.H., Caldwell, C.W.,
and Huang, T.H. (2001). Dissecting complex epigenetic alterations in beast
cancer using CpG island microarrays. Cancer Res. 61, 8375–8380.
